← Back to Search

MRI for ADHD Treatment Response Prediction

N/A
Waitlist Available
Led By Joseph Biederman, MD
Research Sponsored by Massachusetts General Hospital
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 months
Awards & highlights
No Placebo-Only Group

Summary

This trial will test if certain brain markers can predict how well adults with ADHD will respond to stimulant medications.

Eligible Conditions
  • Attention Deficit Hyperactivity Disorder (ADHD)

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 6 months for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
ADHD Clinical Global Impressions Scale - Improvement (CGI-I)
ADHD Clinical Global Impressions Scale - Severity (CGI-S)
Secondary study objectives
Connectomic Variation Prediction of Medicine Response

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

2Treatment groups
Experimental Treatment
Group I: MethylphenidateExperimental Treatment1 Intervention
Adult subjects (ages 18-45) receiving a Methylphenidate derivative medication
Group II: AmphetamineExperimental Treatment1 Intervention
Adult subjects (ages 18-45) receiving an Amphetamine derivative medication
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
MRI
2009
Completed Phase 2
~2810

Find a Location

Who is running the clinical trial?

Massachusetts Institute of TechnologyOTHER
98 Previous Clinical Trials
12,819,927 Total Patients Enrolled
1 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
41 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Massachusetts General HospitalLead Sponsor
3,000 Previous Clinical Trials
13,308,486 Total Patients Enrolled
59 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
8,479 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)
Joseph Biederman, MDPrincipal InvestigatorMassachusetts General Hospital
24 Previous Clinical Trials
6,374 Total Patients Enrolled
13 Trials studying Attention Deficit Hyperactivity Disorder (ADHD)
4,444 Patients Enrolled for Attention Deficit Hyperactivity Disorder (ADHD)

Media Library

MRI Clinical Trial Eligibility Overview. Trial Name: NCT03153488 — N/A
Attention Deficit Hyperactivity Disorder (ADHD) Research Study Groups: Amphetamine, Methylphenidate
Attention Deficit Hyperactivity Disorder (ADHD) Clinical Trial 2023: MRI Highlights & Side Effects. Trial Name: NCT03153488 — N/A
MRI 2023 Treatment Timeline for Medical Study. Trial Name: NCT03153488 — N/A
~8 spots leftby Oct 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top